Hematology
News
Eating olive oil may slow CLL disease progression
A pilot study in Greece suggested that consuming extra virgin olive oil daily induced the apoptosis of cancer cells.
Article
Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera
Patients with polycythemia vera, a chronic myeloproliferative neoplasm, have a greater morbidity and mortality risk than the general population,...
News
Complex link between gut microbiome and immunotherapy response in advanced melanoma
Previous studies have identified the gut microbiome as “a potential biomarker of response as well as a therapeutic target” in melanoma and other...
News
FDA approves new CAR T-cell treatment for multiple myeloma
Study results show that this treatment for refractory/relapsed multiple myeloma can provide deep, durable responses and long treatment-free...
News
Stopping venetoclax treatment early reduces CLL survival outcomes
Survival outcomes are decreased with early, permanent discontinuation of venetoclax but unchanged by treatment interruption, regardless of...
News
CLL patients ‘cured’: 10 years post infusion, CAR T cells persist
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
News
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...
News
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response following a COVID-19 vaccine...
News
‘Highly encouraging’ MRD results for zanubrutinib add-on in CLL
Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.
Conference Coverage
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...